A prostate cancer treatment using permanently implanted radioactive 'seeds' doubles rates of five-year tumour-free survival compared with
conventional high-dose radiotherapy, a study has found. Low-dose-rate
prostate Brachytherapy (LDR-PB) involves the insertion of tiny
radioactive implants into the prostate gland which are not removed.
A new trial
comparing the treatment with dose-escalated external beam radiotherapy
found that it was much more successful at banishing cancer.
Men who underwent LDR-PB were twice as likely to be cancer-free five years later.
Scientists studied 398 men with cancer that had not spread outside
the prostate gland who were judged to be at high risk of treatment
failure based on standard test results.
Lead researcher Professor James Morris, from Vancouver Cancer Centre in Canada, said, “At five years follow up, we saw a large advantage in progression-free survival in the LDR-PB group.
“Although,
to date, overall survival and prostate cancer-specific survival do not
appear to differ between the two groups, existing trends favour LDR-PB
and an overall survival advantage is likely to emerge with longer
follow-up.”
The findings were presented at the third European Society for Radiotherapy and Oncology forum in Barcelona, Spain.
No comments:
Post a Comment